Jazz Pharmaceuticals (JAZZ) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $5.71
- EPS estimate
- $6.18
- EPS surprise
- −7.53%
- Revenue surprise
- +8.42%
- Revenue
- $1.2B
- Revenue estimate
- $1.1B
- Reported
- Aug 3, 2026
Jazz Pharmaceuticals reported Q2 2026 results on August 3, 2026. Earnings per share were $5.71, below the $6.18 estimate by 7.53%. Revenue was $1.2 billion, ahead of the $1.1 billion consensus. A year earlier, in Q2 2025, Jazz posted a loss of $8.25 per share on revenue of $1.0 billion, so the latest quarter marks a return to profit for that period.
The longer record is uneven. Annual EPS rose from $13.13 in 2022 to $18.32 in 2023 and $21.19 in 2024, then fell about 61% to $8.20 in 2025. That loss is the lowest quarter in the table; the only other loss was Q4 2022, at $0.07 per share. The first half of 2026 adds up to $12.05, compared with a net loss of $6.57 for the first half of 2025. Quarterly revenue grew from $813.7 million in Q1 2022 to $1.1–1.2 billion recently. Over the last 20 quarters, Jazz beat the EPS estimate 11 times and missed 9 times.
Jazz reported its third quarter between November 5 and November 9 in each of the past five years. That points to early November 2026 for the Q3 report. It will show whether profits stay near recent levels.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 3, 2026 | $6.18 | $5.71 | −7.53% | $1.2B | SEC |
| Q1 2026 | May 5, 2026 | $4.66 | $6.34 | +36.17% | $1.1B | SEC |
| Q4 2025 | Feb 24, 2026 | $6.52 | $6.64 | +1.88% | $1.2B | SEC |
| Q3 2025 | Nov 5, 2025 | $5.95 | $8.13 | +36.72% | $1.1B | SEC |
| Q2 2025 | Aug 5, 2025 | −$7.61 | −$8.25 | −8.47% | $1.0B | SEC |
| Q1 2025 | May 6, 2025 | $4.66 | $1.68 | −63.93% | $897.8M | SEC |
| Q4 2024 | Feb 25, 2025 | $5.86 | $6.60 | +12.60% | $1.1B | SEC |
| Q3 2024 | Nov 6, 2024 | $5.50 | $6.61 | +20.22% | $1.1B | SEC |
| Q2 2024 | Jul 31, 2024 | $4.92 | $5.30 | +7.68% | $1.0B | SEC |
| Q1 2024 | May 1, 2024 | $4.18 | $2.68 | −35.87% | $902.0M | SEC |
| Q4 2023 | Feb 28, 2024 | $5.18 | $5.02 | −3.18% | $1.0B | SEC |
| Q3 2023 | Nov 8, 2023 | $4.93 | $4.84 | −1.88% | $972.1M | SEC |
| Q2 2023 | Aug 9, 2023 | $4.45 | $4.51 | +1.45% | $957.3M | SEC |
| Q1 2023 | May 10, 2023 | $4.24 | $3.95 | −6.83% | $892.8M | SEC |
| Q4 2022 | Mar 1, 2023 | $0.88 | −$0.07 | −107.93% | $972.1M | SEC |
| Q3 2022 | Nov 9, 2022 | $4.66 | $5.17 | +10.93% | $940.7M | SEC |
| Q2 2022 | Aug 3, 2022 | $4.18 | $4.30 | +2.91% | $932.9M | SEC |
| Q1 2022 | May 4, 2022 | $3.84 | $3.73 | −2.86% | $813.7M | SEC |
| Q4 2021 | Mar 1, 2022 | $3.63 | $4.21 | +15.95% | $896.7M | SEC |
| Q3 2021 | Nov 9, 2021 | $3.32 | $4.20 | +26.56% | $838.1M | SEC |
Quarterly revenue
Frequently asked questions
When did Jazz Pharmaceuticals (JAZZ) last report earnings?
Jazz Pharmaceuticals last reported on Aug 3, 2026, covering fiscal Q2 2026.
Did JAZZ beat earnings estimates?
No. Jazz Pharmaceuticals reported EPS of $5.71 for Q2 2026 against a $6.18 estimate — a 7.53% miss.
How much revenue did JAZZ report last quarter?
Jazz Pharmaceuticals reported $1.2B in revenue for Q2 2026, against a consensus estimate of $1.1B.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.